Treatment of Nontuberculous Mycobacterial Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines

Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.

Automated summary

Less than half of the participants with pulmonary Mycobacterium avium complex and Mycobacterium abscessus received guideline-based antibiotic therapy before enrollment in the US Bronchiectasis and NTM Research Registry. Adverse effects occurred in 21% of therapy recipients, with 33% discontinuing therapy.